SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Wenlian Li, Hongzong Si, Yang Li, Cuizhu Ge, Fucheng Song, Xiuting Ma, Yunbo Duan, Honglin Zhai, 3D-QSAR and molecular docking studies on designing inhibitors of the hepatitis C virus NS5B polymerase, Journal of Molecular Structure, 2016, 1117, 227

    CrossRef

  2. 2
    Chueh-Yao Chung, Ching-Hsuan Liu, Thierry Burnouf, Guey-Horng Wang, Shun-Pang Chang, Alagie Jassey, Chen-Jei Tai, Cheng-Jeng Tai, Ching-Jang Huang, Christopher D. Richardson, Ming-Hong Yen, Chun-Ching Lin, Liang-Tzung Lin, Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry, Antiviral Research, 2016, 130, 58

    CrossRef

  3. 3
    Tarik Asselah, Nathalie Boyer, David Saadoun, Michele Martinot-Peignoux, Patrick Marcellin, Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives, Liver International, 2016, 36,
  4. 4
    Yundong Qu, Tao Li, Lei Wang, Feng Liu, Qian Ye, Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis, Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 2, 203

    CrossRef

  5. 5
    Akihiro Tamori, Masaru Enomoto, Norifumi Kawada, Recent Advances in Antiviral Therapy for Chronic Hepatitis C, Mediators of Inflammation, 2016, 2016, 1

    CrossRef

  6. 6
    Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. Kyne, Kevin K.-C. Liu, Sarah J. Fink, Christopher J. O’Donnell, Synthetic approaches to the 2014 new drugs, Bioorganic & Medicinal Chemistry, 2016, 24, 9, 1937

    CrossRef

  7. 7
    Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Guglielmo Borgia, Beclabuvir for the treatment of hepatitis C, Expert Opinion on Investigational Drugs, 2015, 24, 8, 1111

    CrossRef

  8. 8
    Fabao Zhao, Na Liu, Peng Zhan, Xuemei Jiang, Xinyong Liu, Discovery of HCV NS5B thumb site I inhibitors: Core-refining from benzimidazole to indole scaffold, European Journal of Medicinal Chemistry, 2015, 94, 218

    CrossRef

  9. You have free access to this content9
    Akira Okajima, Kanji Yamaguchi, Hiroyoshi Taketani, Tasuku Hara, Hiroshi Ishiba, Yuya Seko, Takeshi Nishimura, Taichiroh Nishikawa, Hideki Fujii, Michihisa Moriguchi, Hironori Mitsuyoshi, Yoshio Sumida, Kohichiroh Yasui, Masahito Minami, Yoshito Itoh, Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir, Hepatology Research, 2015, 45, 10
  10. 10
    C. Estes, M. Abdel-Kareem, W. Abdel-Razek, E. Abdel-Sameea, M. Abuzeid, A. Gomaa, W. Osman, H. Razavi, H. Zaghla, I. Waked, Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies, Alimentary Pharmacology & Therapeutics, 2015, 42, 6
  11. 11
    Ewa Janczewska, Robert Flisiak, Dorota Zarebska-Michaluk, Dorota Kozielewicz, Hanna Berak, Beata Dobracka, Marta Librant-Suska, Wladyslaw Lojewski, Krzysztof Jurczyk, Joanna Musialik, Barbara Postawa-Klosińska, Jacek Wroblewski, Krystyna Augustyniak, Marek Dudziak, Iwona Olszok, Agata Ruszala, Arkadiusz Pisula, Tadeusz Lapinski, Wieslaw Kryczka, Andrzej Horban, Witold Dobracki, Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis, Medicine, 2015, 94, 38, e1411

    CrossRef

  12. 12
    Shaojun Zhu, Yanhong Li, Yang Zhang, Xuxia Wang, Li Gong, Xiujuan Han, Li Yao, Miao Lan, Wei Zhang, Expression and clinical implications of HAb18G/CD147 in hepatocellular carcinoma, Hepatology Research, 2015, 45, 1
  13. 13
    Marc Bourlière, Tarik Asselah, HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015, Current Hepatology Reports, 2015, 14, 4, 260

    CrossRef

  14. 14
    Inge Vliegen, Jan Paeshuyse, Weidong Zhong, Johan Neyts, In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance, Antiviral Research, 2015, 120, 112

    CrossRef

  15. 15
    Wen-Chan Hsu, Shun-Pang Chang, Lie-Chwen Lin, Chia-Lin Li, Christopher D. Richardson, Chun-Ching Lin, Liang-Tzung Lin, Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry, Antiviral Research, 2015, 118, 139

    CrossRef

  16. You have free access to this content16
    Tarik Asselah, Patrick Marcellin, Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection, Liver International, 2015, 35,
  17. You have free access to this content17
    C. Bunchorntavakul, K. R. Reddy, Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection, Alimentary Pharmacology & Therapeutics, 2015, 42, 3
  18. 18
    M. P. Manns, M. W. Fried, S. Zeuzem, I. M. Jacobson, X. Forns, F. Poordad, M. Peeters, M. Fu, O. Lenz, S. Ouwerkerk-Mahadevan, W. Jessner, J. A. Scott, R. Kalmeijer, G. De La Rosa, R. Sinha, M. Beumont-Mauviel, Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies, Journal of Viral Hepatitis, 2015, 22, 4
  19. 19
    Qi-Fei Zhong, Rui Liu, Gang Liu, Structure–activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870, Molecular Diversity, 2015, 19, 4, 829

    CrossRef

  20. 20
    A. A. Artenie, D. Jutras-Aswad, É. Roy, G. Zang, J.-M. Bamvita, A. Lévesque, J. Bruneau, Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement, Journal of Viral Hepatitis, 2015, 22, 10
  21. 21
    Long Yuan, Hao Jiang, Naiyu Zheng, Yuan-Qing Xia, Zheng Ouyang, Jianing Zeng, Billy Akinsanya, Jack L. Valentine, Jeffrey D. Moehlenkamp, Yuzhong Deng, Anne-Françoise Aubry, Mark E. Arnold, A validated LC–MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma, Journal of Chromatography B, 2014, 973, 1

    CrossRef

  22. 22
    Steven J. Coats, Ethel C. Garnier-Amblard, Franck Amblard, Maryam Ehteshami, Sheida Amiralaei, Hongwang Zhang, Longhu Zhou, Sebastien R.L. Boucle, Xiao Lu, Lavanya Bondada, Jadd R. Shelton, Hao Li, Peng Liu, Chengwei Li, Jong Hyun Cho, Satish N. Chavre, Shaoman Zhou, Judy Mathew, Raymond F. Schinazi, Chutes and ladders in hepatitis C nucleoside drug development, Antiviral Research, 2014, 102, 119

    CrossRef

  23. 23
    Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, Maxwell D. Cummings, Oliver Lenz, Pierre Raboisson, Kenny Simmen, Sandrine Vendeville, Herman de Kock, Magnus Nilsson, Andras Horvath, Ronald Kalmeijer, Guy de la Rosa, Maria Beumont-Mauviel, Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor, Journal of Medicinal Chemistry, 2014, 57, 5, 1673

    CrossRef

  24. 24
    Ramesh Kakarla, Jian Liu, Devan Naduthambi, Wonsuk Chang, Ralph T. Mosley, Donghui Bao, Holly M. Micolochick Steuer, Meg Keilman, Shalini Bansal, Angela M. Lam, William Seibel, Sandra Neilson, Phillip A. Furman, Michael J. Sofia, Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives, Journal of Medicinal Chemistry, 2014, 57, 5, 2136

    CrossRef

  25. 25
    Francisco X. Talamas, Sarah C. Abbot, Shalini Anand, Ken A. Brameld, David S. Carter, Jun Chen, Dana Davis, Javier de Vicente, Amy D. Fung, Leyi Gong, Seth F. Harris, Petra Inbar, Sharada S. Labadie, Eun K. Lee, Remy Lemoine, Sophie Le Pogam, Vincent Leveque, Jim Li, Joel McIntosh, Isabel Nájera, Jaehyeon Park, Aruna Railkar, Sonal Rajyaguru, Michael Sangi, Ryan C. Schoenfeld, Leanna R. Staben, Yunchou Tan, Joshua P. Taygerly, Armando G. Villaseñor, Paul E. Weller, Discovery ofN-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase, Journal of Medicinal Chemistry, 2014, 57, 5, 1914

    CrossRef

  26. You have free access to this content26
    Raymond Schinazi, Philippe Halfon, Patrick Marcellin, Tarik Asselah, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, 2014, 34,
  27. 27
    John F. Miller, Pek Y. Chong, J. Brad Shotwell, John G. Catalano, Vincent W.-F. Tai, Jing Fang, Anna L. Banka, Christopher D. Roberts, Michael Youngman, Huichang Zhang, Zhiping Xiong, Amanda Mathis, Jeffery J. Pouliot, Robert K. Hamatake, Daniel J. Price, John W. Seal, Lisa L. Stroup, Katrina L. Creech, Luz H. Carballo, Dan Todd, Andrew Spaltenstein, Sylvia Furst, Zhi Hong, Andrew J. Peat, Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein, Journal of Medicinal Chemistry, 2014, 57, 5, 2107

    CrossRef

  28. 28
    J. W. Galbraith, J. P. Donnelly, R. A. Franco, E. T. Overton, J. B. Rodgers, H. E. Wang, National Estimates of Healthcare Utilization by Individuals With Hepatitis C Virus Infection in the United States, Clinical Infectious Diseases, 2014, 59, 6, 755

    CrossRef

  29. 29
    Wael Abdel-Razek, Imam Waked, Optimal Management of HCV Genotype 4, Current Hepatology Reports, 2014, 13, 4, 286

    CrossRef

  30. You have free access to this content30
    A. F. Stättermayer, T. Scherzer, S. Beinhardt, K. Rutter, H. Hofer, P. Ferenci, Review article: genetic factors that modify the outcome of viral hepatitis, Alimentary Pharmacology & Therapeutics, 2014, 39, 10
  31. 31
    Michael Manns, Patrick Marcellin, Fred Poordad, Evaldo Stanislau Affonso de Araujo, Maria Buti, Yves Horsmans, Ewa Janczewska, Federico Villamil, Jane Scott, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Guy De La Rosa, Ronald Kalmeijer, Rekha Sinha, Maria Beumont-Mauviel, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet, 2014, 384, 9941, 414

    CrossRef

  32. 32
    Ira M Jacobson, Gregory J Dore, Graham R Foster, Michael W Fried, Monica Radu, Vladimir V Rafalsky, Larysa Moroz, Antonio Craxi, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Guy De La Rosa, Ronald Kalmeijer, Jane Scott, Rekha Sinha, Maria Beumont-Mauviel, Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial, The Lancet, 2014, 384, 9941, 403

    CrossRef

  33. 33
    Imam Waked, Waheed Doss, Manal Hamdy El-Sayed, Chris Estes, Homie Razavi, Gamal Shiha, Ayman Yosry, Gamal Esmat, The current and future disease burden of chronic hepatitis C virus infection in Egypt, Arab Journal of Gastroenterology, 2014, 15, 2, 45

    CrossRef

  34. 34
    S.A. Weinman, R. Taylor, Pathobiology of Human Disease, 2014,

    CrossRef

  35. 35
    Cécile Enguehard-Gueiffier, Simone Musiu, Nicolas Henry, Jean-Baptiste Véron, Sylvie Mavel, Johan Neyts, Pieter Leyssen, Jan Paeshuyse, Alain Gueiffier, 3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and analogues, novel Flaviviridae inhibitors, European Journal of Medicinal Chemistry, 2013, 64, 448

    CrossRef

  36. 36
    Yuji Urabe, Hidenori Ochi, Naoya Kato, Vinod Kumar, Atsushi Takahashi, Ryosuke Muroyama, Naoya Hosono, Motoyuki Otsuka, Ryosuke Tateishi, Paulisally Hau Yi Lo, Chizu Tanikawa, Masao Omata, Kazuhiko Koike, Daiki Miki, Hiromi Abe, Naoyuki Kamatani, Joji Toyota, Hiromitsu Kumada, Michiaki Kubo, Kazuaki Chayama, Yusuke Nakamura, Koichi Matsuda, A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region, Journal of Hepatology, 2013, 58, 5, 875

    CrossRef

  37. 37
    Long Yuan, Hao Jiang, Zheng Ouyang, Yuan-Qing Xia, Jianing Zeng, Qianping Peng, Robert W. Lange, Yuzhong Deng, Mark E. Arnold, Anne-Françoise Aubry, A rugged and accurate liquid chromatography–tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma, Journal of Chromatography B, 2013, 921-922, 81

    CrossRef

  38. 38
    Yangyang Hu, Shengpeng Wang, Xu Wu, Jinming Zhang, Ruie Chen, Meiwan Chen, Yitao Wang, Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma, Journal of Ethnopharmacology, 2013, 149, 3, 601

    CrossRef

  39. You have free access to this content39
    Audrey Coilly, Bruno Roche, Didier Samuel, Current management and perspectives for HCV recurrence after liver transplantation, Liver International, 2013, 33,
  40. 40
    Jennifer J. Kiser, Charles Flexner, Direct-Acting Antiviral Agents for Hepatitis C Virus Infection, Annual Review of Pharmacology and Toxicology, 2013, 53, 1, 427

    CrossRef

  41. 41
    Ryan C. Schoenfeld, David L. Bourdet, Ken A. Brameld, Elbert Chin, Javier de Vicente, Amy Fung, Seth F. Harris, Eun K. Lee, Sophie Le Pogam, Vincent Leveque, Jim Li, Alfred S.-T. Lui, Isabel Najera, Sonal Rajyaguru, Michael Sangi, Sandra Steiner, Francisco X. Talamas, Joshua P. Taygerly, Junping Zhao, Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B, Journal of Medicinal Chemistry, 2013, 56, 20, 8163

    CrossRef

  42. 42
    Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher, Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial, Hepatology, 2013, 57, 6
  43. 43
    Aaron Cohn, Andrew Aronsohn, HCV Therapy: Treat now or wait?, Current Hepatitis Reports, 2013, 12, 1, 7

    CrossRef

  44. 44
    M.A. Rubio-Lezama, R. López-Alférez, L. Santillán-Arreygue, M. Romero-Figueroa, Hepatitis C genotipo viral 5 en México: reporte de caso con tratamiento exitoso y revisión de la literatura, Revista de Gastroenterología de México, 2013, 78, 3, 191

    CrossRef

  45. 45
    J. González-Moreno, A. Payeras-Cifre, Hepatitis C Virus Infection: Looking for Interferon Free Regimens, The Scientific World Journal, 2013, 2013, 1

    CrossRef

  46. 46
    Lisa C. Casey, William M. Lee, Hepatitis C virus therapy update 2013, Current Opinion in Gastroenterology, 2013, 1

    CrossRef

  47. You have free access to this content47
    Marc Bourlière, Astrid Wendt, Hélène Fontaine, Christophe Hézode, Stanislas Pol, Jean Pierre Bronowicki, How to optimize HCV therapy in genotype 1 patients with cirrhosis, Liver International, 2013, 33,
  48. You have free access to this content48
    Salvatore Petta, Antonio Craxì, How to optimize HCV therapy in genotype 1 patients: predictors of response, Liver International, 2013, 33,
  49. You have free access to this content49
    Gamal Esmat, Mohamed El Kassas, Mohamed Hassany, Mohamed Esmat Gamil, Maisa El Raziky, How to optimize HCV therapy in genotype 4 patients, Liver International, 2013, 33,
  50. 50
    Hideki Nakasone, Saiko Kurosawa, Kimikazu Yakushijin, Shuichi Taniguchi, Makoto Murata, Kazuhiro Ikegame, Takeshi Kobayashi, Tetsuya Eto, Koichi Miyamura, Hisashi Sakamaki, Yasuo Morishima, Tokiko Nagamura, Ritsuro Suzuki, Takahiro Fukuda, Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation, American Journal of Hematology, 2013, 88, 6
  51. 51
    K. Page, M. D. Morris, J. A. Hahn, L. Maher, M. Prins, Injection Drug Use and Hepatitis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention, Clinical Infectious Diseases, 2013, 57, suppl 2, S32

    CrossRef

  52. You have free access to this content52
    Tarik Asselah, Patrick Marcellin, Interferon free therapy with direct acting antivirals for HCV, Liver International, 2013, 33,
  53. You have free access to this content53
    Virginia C. Clark, Joy A. Peter, David R. Nelson, New therapeutic strategies in HCV: second-generation protease inhibitors, Liver International, 2013, 33,
  54. 54
    D Alan Herbst, K Rajender Reddy, NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection, Expert Opinion on Investigational Drugs, 2013, 22, 10, 1337

    CrossRef

  55. 55
    Michael W. Fried, Maria Buti, Gregory J. Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele Smedt, Maria Beumont-Mauviel, Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study, Hepatology, 2013, 58, 6
  56. You have free access to this content56
    Benjamin Maasoumy, Michael P. Manns, Optimal treatment with boceprevir for chronic HCV infection, Liver International, 2013, 33,
  57. You have free access to this content57
    Mitchell L. Shiffman, Yves Benhamou, Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?, Liver International, 2013, 33,
  58. 58
    Yong-Song Guan, Qing He, Role of antiviral therapy in the management of hepatocellular carcinoma, Anti-Cancer Drugs, 2013, 24, 4, 337

    CrossRef

  59. 59
    David Alan Herbst, K Rajender Reddy, Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection, Expert Opinion on Investigational Drugs, 2013, 22, 4, 527

    CrossRef

  60. 60
    John W. Ward, The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States, Clinics in Liver Disease, 2013, 17, 1, 1

    CrossRef

  61. You have free access to this content61
    Patrick Marcellin, Tarik Asselah, Treatment of viral hepatitis: a new era, Liver International, 2013, 33,
  62. 62
    Limin Chen, Shilin Li, Yujia Li, Xiaoqiong Duan, Bing Liu, Ian McGilvray, Ubiquitin-like protein modifiers and their potential for antiviral and anti-HCV therapy, Expert Review of Proteomics, 2013, 10, 3, 275

    CrossRef

  63. 63
    Tarik Asselah, A revolution in HCV treatment with direct-acting antivirals: From non-response to eradication, Journal of Hepatology, 2012, 57, 2, 455

    CrossRef

  64. 64
    Alessio Aghemo, Pietro Lampertico, Massimo Colombo, Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense, Journal of Hepatology, 2012, 57, 6, 1326

    CrossRef

  65. 65
    John W. Ward, David B. Rein, Bryce D. Smith, Data to Guide the “Test and Treat Era” of Hepatitis C, Gastroenterology, 2012, 143, 4, 887

    CrossRef

  66. 66
    J. W. Ward, R. O. Valdiserri, H. K. Koh, Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice, Clinical Infectious Diseases, 2012, 55, suppl 1, S58

    CrossRef

  67. 67
    Tarik Asselah, Interferon Stimulated Genes and Hepatitis C Virus Infection, Journal of Interferon & Cytokine Research, 2012, 32, 12, 557

    CrossRef

  68. 68
    M. Corouge, S. Pol, Nouveaux traitements de l’infection chronique par le virus de l’hépatite C, Réanimation, 2012, 21, 3, 334

    CrossRef

  69. 69
    Mortada El-Shabrawi, Mortada El-Shabrawi, Mona Isa, Mona Isa, Sustained Viral Response and Hematological Adverse Events During Chronic Hepatitis C Infection Treatment, Hepatitis Monthly, 2012, 12, 2, 122

    CrossRef

  70. 70
    Erik De Clercq, The race for interferon-free HCV therapies: a snapshot by the spring of 2012, Reviews in Medical Virology, 2012, 22, 6
  71. 71
    Tarik Asselah, Triple therapy with boceprevir or telaprevir for prior HCV non-responders, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 455

    CrossRef

  72. 72
    Joanne Bronson, Murali Dhar, William Ewing, Nils Lonberg, Annual Reports in Medicinal Chemistry Volume 47, 2012,

    CrossRef